GlaxoSmithKline To Sell US Wellbutrin XL Rights For $510 Million
<p>May 6, 2009 (FinancialWire) — Drugmaker GlaxoSmithKline plc (NYSE: GSK) said it has entered into an agreement to divest full commercial rights to anti-depression drug Wellbutrin XL in the United States to Biovail Corp.’s (NYSE: …